Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 11, 2023 | August 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date August 11, 2023 · Filed August 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 16,068 |
Ending reported balance
After 2023-08-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-08-11 · Grant · Acquired 3,075 · Balance 17,309 F1: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Row 2 · 2023-08-14 · Sale · Disposed 1,241 · Balance 16,068 F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.75 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024.
F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.75 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2023 Filed Aug 15, 2023 21:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,241 | $138.16 | $171,454.57 |
DisclosureSEC source: 0001765581-23-000080 · edgardoc.xml · nonDerivative · entry 2 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,068 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.75 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000080 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,309 F1 · kind: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $55.28 | $0.00 |
DisclosureSEC source: 0001765581-22-000106 · edgardoc.xml · derivative · entry 3 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,000 shares Expires 2023-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan. Subject to the Reporting Person's continuous service and certain additional conditions, this option vested over three years from the Vesting Commencement Date, with 1/3 that vested on the first anniversary of the Vesting Commencement Date and the remainder vested in 24 equal monthly installments thereafter. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 8,000 | $158.00 | $1,264,000.00 |
DisclosureSEC source: 0001765581-22-000106 · edgardoc.xml · nonDerivative · entry 2 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,234 Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 8,000 | $55.28 | $442,240.00 |
DisclosureSEC source: 0001765581-22-000106 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,179 | $152.32 | $179,588.11 |
DisclosureSEC source: 0001765581-22-000086 · edgardoc.xml · nonDerivative · entry 2 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,234 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000086 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,413 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,414 | $147.96 | $209,215.44 |
DisclosureSEC source: 0001765581-21-000102 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,852 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000071 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,266 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,765 | $0.00 Strike: $127.07 | $0.00 |
DisclosureSEC source: 0001765581-20-000071 · edgardoc.xml · derivative · entry 2 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Underlying: Ordinary Shares · 6,765 shares Expires 2030-08-05 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000071 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,020 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 787 | $135.65 | $106,756.86 |
DisclosureSEC source: 0001765581-19-000064 · edgardoc.xml · nonDerivative · entry 2 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,315 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.65 to $135.7132. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,805 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001765581-19-000064 · edgardoc.xml · derivative · entry 3 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Ordinary Shares · 4,805 shares Expires 2029-08-07 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000064 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,102 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020. Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 715 | $176.61 | $126,276.58 |
DisclosureSEC source: 0001232524-18-000150 · edgardoc.xml · nonDerivative · entry 2 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,182 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.61 to $177.0615. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,735 | $0.00 Strike: $177.73 | $0.00 |
DisclosureSEC source: 0001232524-18-000150 · edgardoc.xml · derivative · entry 3 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,735 Underlying: Ordinary Shares · 3,735 shares Expires 2028-08-08 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000150 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,897 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3 | $144.22 | $432.65 |
DisclosureSEC source: 0001232524-17-000140 · edgardoc.xml · nonDerivative · entry 3 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,402 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 714 | $142.36 | $101,645.04 |
DisclosureSEC source: 0001232524-17-000140 · edgardoc.xml · nonDerivative · entry 2 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,405 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,415 | $0.00 Strike: $143.66 | $0.00 |
DisclosureSEC source: 0001232524-17-000140 · edgardoc.xml · derivative · entry 4 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,415 Underlying: Ordinary Shares · 3,415 shares Expires 2027-08-09 F3 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000140 · edgardoc.xml · nonDerivative · entry 1 Gray Peter · CIK 0001576096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,119 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. F1 · shares: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.